Quoin Pharmaceuticals Ltd
QNRX6.795USD
-0.025-0.36%
Market hours （ET）Quotes delayed by 15 min
139.89MMarket Cap
LossP/E TTM
More Details of Quoin Pharmaceuticals Ltd Company
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Company Info
Ticker SymbolQNRX
Company nameQuoin Pharmaceuticals Ltd
IPO dateNov 01, 1989
CEODr. Michael Myers, Ph.D.
Number of employees3
Security typeDepository Receipt
Fiscal year-endNov 01
Address23 Hata'as Street
CityKFAR SABA
Stock exchangeNASDAQ Capital Market Consolidated
CountryIsrael
Postal code44425
Phone97299741444
Websitehttps://quoinpharma.com/
Ticker SymbolQNRX
IPO dateNov 01, 1989
CEODr. Michael Myers, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
17.22K
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. Eyal Leibovitz
Mr. Eyal Leibovitz
Chief Financial Officer
Chief Financial Officer
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Mr. Yali Sheffi
Mr. Yali Sheffi
Independent External Director
Independent External Director
--
--
Mr. Guy Sapir
Mr. Guy Sapir
Internal Auditor
Internal Auditor
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
17.22K
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. Eyal Leibovitz
Mr. Eyal Leibovitz
Chief Financial Officer
Chief Financial Officer
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Jul 26
Updated: Sat, Jul 26
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Myers (Michael)
2.93%
Carter (Denise P)
2.93%
UBS Financial Services, Inc.
1.07%
Dunn (Gordon)
0.73%
Culverwell (Anthony James)
0.49%
Other
91.86%
Shareholders
Shareholders
Proportion
Myers (Michael)
2.93%
Carter (Denise P)
2.93%
UBS Financial Services, Inc.
1.07%
Dunn (Gordon)
0.73%
Culverwell (Anthony James)
0.49%
Other
91.86%
Shareholder Types
Shareholders
Proportion
Individual Investor
7.08%
Investment Advisor
1.44%
Investment Advisor/Hedge Fund
0.16%
Other
91.32%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
33
51.05K
8.68%
-35.06K
2025Q1
35
78.22K
9.34%
-7.90K
2024Q4
33
2.93M
35.77%
+2.56M
2024Q3
29
288.95K
5.54%
-93.09K
2024Q2
30
301.96K
12.37%
-13.30K
2024Q1
28
276.13K
11.96%
+132.88K
2023Q4
28
104.03K
10.54%
-33.36K
2023Q3
27
83.72K
8.48%
+6.49K
2023Q2
28
91.62K
18.66%
+37.20K
2023Q1
30
101.74K
19.68%
+59.45K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Myers (Michael)
17.22K
2.93%
--
--
Mar 10, 2025
Carter (Denise P)
17.22K
2.93%
+1.00
+0.01%
Mar 10, 2025
UBS Financial Services, Inc.
6.27K
1.07%
+6.13K
+4507.35%
Mar 31, 2025
Dunn (Gordon)
4.32K
0.73%
--
--
Mar 10, 2025
Culverwell (Anthony James)
2.87K
0.49%
+2.86K
+31744.44%
Mar 10, 2025
Rhumbline Advisers Ltd. Partnership
1.19K
0.2%
+504.00
+73.15%
Mar 31, 2025
Raymond James Financial Services Advisors, Inc.
718.00
0.12%
--
--
Mar 31, 2025
Lido Advisors, LLC
672.00
0.11%
+672.00
--
Mar 31, 2025
Susquehanna International Group, LLP
320.00
0.05%
+320.00
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 26, 2025
Merger
20<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jul 29, 2022
Merger
12.5<1
Date
Type
Ratio
Mar 26, 2025
Merger
20<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jul 29, 2022
Merger
12.5<1
Jul 29, 2022
Merger
12.5<1
Jul 29, 2022
Merger
12.5<1
Jul 29, 2022
Merger
12.5<1
Sep 23, 2021
Merger
4<1
View more
